Despite ongoing efforts to stimulate investment and research into the development of new antibiotics, the clinical pipeline remains insufficient, in particular to treat critical resistant Gram-negative bacterial infections. The two new reports released by the World Health Organization on the preclinical and clinical antibacterial pipeline show that the current clinical pipeline is very dry and dominated by derivatives of existing classes. There are only 32 antibacterials in the clinical pipeline that target the WHO priority pathogens, of which only 6 fulfill at least 1 of the innovation criteria as defined by the WHO. Further upstream, the preclinical pipeline review identified 252 antibacterial agents in preclinical development of which over one third are nontraditioanl products which highlights the degree of innovation in the preclinical pipeline. The pipeline is also heavily reliant on small- or medium-sized enterprises, which is unsustainable in the long run, and more investment, more players, and a rethinking of the market dynamics is needed. It is encouraging that the pharmaceutical industry, governments, and other concerned stakeholders are currently discussing new ideas.

中文翻译：

---

抗菌研发管道需要紧急解决方案

尽管一直在努力刺激投资和研究新抗生素的研发，但是临床途径仍然不足，特别是不能治疗关键的耐药革兰氏阴性细菌感染。世界卫生组织发布的关于临床前和临床抗菌药水管道的两份新报告显示，当前的临床药水管道非常干燥，并以现有类别的衍生物为主导。临床上只有32种针对WHO优先病原体的抗菌剂，其中只有6种满足WHO定义的至少一项创新标准。在更上游，临床前管线审查确定了252种在临床前开发中使用的抗菌剂，其中三分之一以上是非传统的产品，这突出了临床前管线的创新程度。管道还严重依赖于中小型企业，从长远来看，这是不可持续的，因此需要更多的投资，更多的参与者以及对市场动态的重新思考。令人鼓舞的是，制药行业，政府和其他有关利益方目前正在讨论新的想法。